Hepatosplenic gamma-delta T-cell lymphoma

Critical Reviews in Oncology/Hematology

Volumn 83, Issue 2, 2012, Pages 283-292

  Ferreri, Andrés J M ^a   Govi, Silvia ^a   Pileri, Stefano A ^b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

2' Deoxycoformycin; Alemtuzumab; Extranodal lymphoma; Hepatosplenic lymphoma; T cell lymphoma

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ALEMTUZUMAB; ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ASPARAGINASE; AZATHIOPRINE; BORTEZOMIB; CARMUSTINE; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LACTATE DEHYDROGENASE; MELPHALAN; PENTOSTATIN; PLATINUM COMPLEX; PREDNISONE; PURINE DERIVATIVE; RITUXIMAB; THIOTEPA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VINCRISTINE;

ABDOMINAL PAIN; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORPHOLOGY; CANCER PROGNOSIS; CANCER REGRESSION; CANCER RELAPSE; CANCER RESISTANCE; CANCER STAGING; CROHN DISEASE; DIFFERENTIAL DIAGNOSIS; DRUG MEGADOSE; ENTERITIS; FEVER; GAMMA DELTA T LYMPHOCYTE; HEPATOSPLENIC T CELL LYMPHOMA; HEPATOSPLENOMEGALY; HISTOPATHOLOGY; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOSTIMULATION; LEUKOPENIA; LIVER BIOPSY; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; ORGAN TRANSPLANTATION; OVERALL SURVIVAL; REVIEW; RISK FACTOR; SPLENECTOMY; T CELL LYMPHOMA; THROMBOCYTOPENIA; WEAKNESS;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LIVER NEOPLASMS; LYMPHOCYTES; LYMPHOMA, T-CELL; PENTOSTATIN; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; SPLENIC NEOPLASMS;

EID: 84861444831     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.10.001     Document Type: Review

References (70)

1. Ciofani M., Knowles G.C., Wiest D.L., et al. Stage-specific and differential notch dependency at the alphabeta and gammadelta T lineage bifurcation. Immunity 2006, 25(1):105-116.
2. Przybylski G.K., Wu H., Macon W.R., et al. Hepatosplenic and subcutaneous panniculitis-like gamma/delta T cell lymphomas are derived from different Vdelta subsets of gamma/delta T lymphocytes. J Mol Diagn 2000, 2(1 Feb):11-19.
3. Bordessoule D., Gaulard P., Mason D.Y. Preferential localisation of human lymphocytes bearing gamma delta T cell receptors to the red pulp of the spleen. J Clin Pathol 1990, 43(June (6)):461-464.
4. Cooke C.B., Krenacs L., Stetler-Stevenson M., et al. Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. Blood 1996, 88:4265-4274.
5. Ross C.W., Schnitzer B., Sheldon S., Braun D.K., Hanson C.A. Gamma/delta T-cell posttransplantation lymphoproliferative disorder primarily in the spleen. Am J Clin Pathol 1994, 102:310-315.
6. Salhany K.E., Feldman M., Peritt D., Nowell P.C. Cytotoxic T-lymphocyte differentiation and cytogenetic alterations in gammadelta hepatosplenic T-cell lymphoma and posttransplant lymphoproliferative disorders. Blood 1997, 89:3490-3491.
7. Roelandt P.R., Maertens J., Vandenberghe P., et al. Hepatosplenic gammadelta T-cell lymphoma after liver transplantation: report of the first 2 cases and review of the literature. Liver Transplant 2009, 15(July (7)):686-692.
8. Belhadj K., Reyes F., Farcet J.P., et al. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 2003, 102:4261-4269.
9. Rothenberg M.E., Weber W.E., Longtine J.A., et al. Cytotoxic gamma delta I lymphocytes associated with an Epstein-Barr virus-induced posttransplantation lymphoproliferative disorder. Clin Immunol Immunopathol 1996, 80(September (3 Pt 1)):266-272.
10. Ozaki S., Ogasahara K., Kosaka M., et al. Hepatosplenic gamma delta T-cell lymphoma associated with hepatitis B virus infection. J Med Invest 1998, 44:215-217.
11. Mackey A.C., Green L., Liang L.C., Dinndorf P., Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007, 44(February (2)):265-267.
12. Shale M., Kanfer E., Panaccione R., Ghosh S. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut 2008, 57:1639-1641.
13. Siegel C.A., Marden S.M., Persing S.M., et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009, 7(August (8)):874-881.
14. Kandiel A., Fraser A.G., Korelitz B.I., Brensinger C., Lewis J.D. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005, 54(August (8)):1121-1125.
15. Kotlyar DS, Osterman MT, Diamond RH. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol [Epub 2010 Oct 1].
16. Gaulard P., Jaffe E., Krenacs L., Macon W.R. Hepatosplenic T-cell lymphoma. WHO classification of tumours of hematopoietic and lymphoid tissues 2008, 292-293. IARC, Lyon. S.H. Swerdlow (Ed.).
17. Farcet J.P., Gaulard P., Marolleau J.P., et al. Hepatosplenic T-cell lymphoma: sinusal/sinusoidal localization of malignant cells expressing the T-cell receptor gamma delta. Blood 1990, 75:2213-2219.
18. Gaulard P., Bourquelot P., Kanavaros P., et al. Expression of the alpha/beta and gamma/delta T-cell receptors in 57 cases of peripheral T-cell lymphomas. Identification of a subset of gamma/delta T-cell lymphomas. Am J Pathol 1990, 137(September (3)):617-628.
19. de Wolf-Peeters C., Achten R. gammadelta T-cell lymphomas: a homogeneous entity?. Histopathology 2000, 36(April (4)):294-305.
20. Allory Y., Challine D., Haioun C., et al. Bone marrow involvement in lymphomas with hemophagocytic syndrome at presentation: a clinicopathologic study of 11 patients in a Western institution. Am J Surg Pathol 2001, 25(July (7)):865-874.
21. Gaulard P., Belhadj K., Reyes F. Gammadelta T-cell lymphomas. Semin Hematol 2003, 40(July (3)):233-243.
22. Falchook G.S., Vega F., Dang N.H., et al. Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol 2009, 20(June (6)):1080-1085.
23. Florena A.M., Tripodo C., Porcasi R., et al. Immunophenotypic profile and role of adhesion molecules in splenic marginal zone lymphoma with bone marrow involvement. Leuk Lymphoma 2006, 47(January (1)):49-57.
24. Mastovich S., Ratech H., Ware R.E., et al. Hepatosplenic T-cell lymphoma: an unusual case of a gamma delta T-cell lymphoma with a blast-like terminal transformation. Hum Pathol 1994, 25(January (1)):102-108.
25. Swerdlow S., McColl K., Rong Y., et al. Apoptosis inhibition by Bcl-2 gives way to autophagy in glucocorticoid-treated lymphocytes. Autophagy 2008, 4(July (5)):612-620. [Epub 2008 Mar 17].
26. Weidmann E. Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. Leukemia 2000, 14(June (6)):991-997.
27. Vega F., Medeiros L.J., Bueso-Ramos C., et al. Hepatosplenic gamma/delta T-cell lymphoma in bone marrow. A sinusoidal neoplasm with blastic cytologic features. Am J Clin Pathol 2001, 116(September (3)):410-419.
28. Suarez F., Wlodarska I., Rigal-Huguet F., et al. Hepatosplenic alphabeta T-cell lymphoma: an unusual case with clinical, histologic, and cytogenetic features of gammadelta hepatosplenic T-cell lymphoma. Am J Surg Pathol 2000, 24(July (7)):1027-1032.
29. Macon W.R., Levy N.B., Kurtin P.J. Hepatosplenic alphabeta T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas. Am J Surg Pathol 2001, 25(March (3)):285-296.
30. Wang C.C., Tien H.F., Lin M.T., et al. Consistent presence of isochromosome 7q in hepatosplenic T gamma/delta lymphoma: a new cytogenetic-clinicopathologic entity. Genes Chromosomes Cancer 1995, 12:161-164.
31. Wlodarska I., Martin-Garcia N., Achten R., et al. Fluorescence in situ hybridization study of chromosome 7 aberrations in hepatosplenic T-cell lymphoma: isochromosome 7q as a common abnormality accumulating in forms with features of cytologic progression. Genes Chromosomes Cancer 2002, 33(March (3)):243-251.
32. Jonveaux P., Daniel M.T., Martel V., Maarek O., Berger R. Isochromosome 7q and trisomy 8 are consistent primary, non-random chromosomal abnormalities associated with hepatosplenic T gamma/delta lymphoma. Leukemia 1996, 10:1453-1455.
33. Tamaska J., Adam E., Kozma A., et al. Hepatosplenic gammadelta T-cell lymphoma with ring chromosome 7, an isochromosome 7q equivalent clonal chromosomal aberration. Virchows Arch 2006, 449(October (4)):479-483.
34. Alonsozana G.L., Elfath M.D., Mackenzie C., et al. In vitro interference of the red cell substitute pyridoxalated hemoglobin-polyoxyethylene with blood compatibility, coagulation, and clinical chemistry testing. J Cardiothorac Vasc Anesth 1997, 11(December (7)):845-850.
35. Miyazaki K., Yamaguchi M., Imai H., et al. Gene expression profiling of peripheral T-cell lymphoma including gammadelta T-cell lymphoma. Blood 2009, 113(January (5)):1071-1074. [Epub 2008 Oct 27].
36. Sallah S., Smith S.V., Lony L.C., Woodard P., Schmitz J.L., Folds J.D. Gamma/delta T-cell hepatosplenic lymphoma: review of the literature, diagnosis by flow cytometry and concomitant autoimmune hemolytic anemia. Ann Hematol 1997, 74:139-142.
37. Iannitto E., Tripodo C. How I diagnose and treat splenic lymphomas. Blood 2011, 117(March (9)):2585-2595.
38. Vega F., Medeiros L.J., Gaulard P. Hepatosplenic and other gammadelta T-cell lymphomas. Am J Clin Pathol 2007, 127(June (6)):869-880.
39. Nosari A., Oreste P.L., Biondi A., et al. Hepato-splenic gammadelta T-cell lymphoma: a rare entity mimicking the hemophagocytic syndrome. Am J Hematol 1999, 60:61-65.
40. Ascani S., Leoni P., Fraternali Orcioni G., et al. T-cell prolymphocytic leukaemia: does the expression of CD8+ phenotype justify the identification of a new subtype? Description of two cases and review of the literature. Ann Oncol 1999, 10(June (6)):649-653.
41. Carbone P.P., Kaplan H.S., Musshoff K., Smithers D.W., Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971, 31:1860-1861.
42. Mastovich S., Ratech H., Ware R.E., Moore J.O., Borowitz M.J. Hepatosplenic T-cell lymphoma: an unusual case of a gamma delta T-cell lymphoma with a blast-like terminal transformation. Hum Pathol 1994, 25:102-108.
43. Gallamini A., Stelitano C., Calvi R., et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004, 103(April (7)):2474-2479.
44. Savage K.J., Chhanabhai M., Gascoyne R.D., et al. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004, 15(October (10)):1467-1475.
45. Gumbs A.A., Zain J., Neylon E., MacGregor-Cortelli B., Patterson M., O'Connor O.A. Importance of early splenectomy in patients with hepatosplenic T-cell lymphoma and severe thrombocytopenia. Ann Surg Oncol 2009, 16(7):2014-2017.
46. Otrock Z.K., Hatoum H.A., Salem Z.M. Long-term remission in a patient with hepatosplenic gammadelta T cell lymphoma treated with bortezomib and high-dose CHOP-like chemotherapy followed by autologous peripheral stem cell transplantation. Ann Hematol 2008, 87(December (12)):1023-1024.
47. Procházka V., Papajík T., Jarosová M., et al. T-cell gamma/delta hepatosplenic lymphoma-prolonged remission induced by aggressive first line treatment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2005, 149(December (2)):275-276.
48. Iannitto E., Barbera V., Quintini G., Cirrincione S., Leone M. Hepatosplenic gammadelta T-cell lymphoma: complete response induced by treatment with pentostatin. Br J Haematol 2002, 117:995-996.
49. Schafer E., Chen A., Arceci R.J. Sustained first remission in an adolescent with hepatosplenic T-cell lymphoma treated with T-cell leukemia induction, nucleoside analog-based consolidation, and early hematopoietic stem cell transplant. Pediatr Blood Cancer 2009, 53(December (6)):1127-1129.
50. He H., Cheng L., Weiss L.M., et al. Clinical outcome of incidental pelvic node malignant B-cell lymphomas discovered at the time of radical prostatectomy. Leuk Lymphoma 2007, 48(October (10)):1976-1980.
51. Konuma T., Ooi J., Takahashi S., et al. Allogeneic stem cell transplantation for hepatosplenic gammadelta T-cell lymphoma. Leuk Lymphoma 2007, 48(March (3)):630-632.
52. Ooi J., Iseki T., Adachi D., et al. Successful allogeneic bone marrow transplantation for hepatosplenic gammadelta T cell lymphoma. Haematologica 2001, 86(October (10)):E25.
53. Bennett M., Matutes E., Gaulard P., Hepatosplenic T cell lymphoma responsive to 2'-deoxycoformycin therapy. Am J Hematol 2010, 85(September (9)):727-729.
54. Domm J.A., Thompson M., Kuttesch J.F. Allogeneic bone marrow transplantation for chemotherapy-refractory hepatosplenic gammadelta T-cell lymphoma: case report and review of the literature. J Pediatr Hematol Oncol 2005, 27(November (11)):607-610.
55. Gassas A., Kirby M., Weitzman S., Ngan B. Hepatosplenic gammadelta T-cell lymphoma in a 10-year-old boy successfully treated with hematopoietic stem cell transplantation. Am J Hematol 2004, 75(February (2)):113-114.
56. Takaku T., Miyazawa K., Sashida G., et al. Hepatosplenic alphabeta T-cell lymphoma with myelodysplastic syndrome. Int J Hematol 2005, 82(August (2)):143-147.
57. Mittal S., Milner B.J., Johnston P.W. A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab. Eur J Haematol 2006, 76(June (6)):531.
58. Sakai R., Fujisawa S., Fujimaki K. Long-term remission in a patient with hepatosplenic gammadelta T cell lymphoma after cord blood stem cell transplantation following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2006, 37(March (5)):537-538.
59. Chen A.I., McMillan A., Negrin R.S., Horning S.J., Laport G.G. Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Biol Blood Marrow Transplant 2008, 14(7):741-747.
60. Le Gouill S., Milpied N., Buzyn A., et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire. J Clin Oncol 2008, 26(May (14)):2264-2271.
61. Aldinucci D., Poletto D., Zagonel V., et al. In vitro and in vivo effects of 2'-deoxycoformycin (pentostatin) on tumour cells from human gammadelta+T-cell malignancies. Br J Haematol 2000, 110:188-196.
62. Grigg A.P. 2'-Deoxycoformycin for hepatosplenic gammadelta T-cell lymphoma. Leuk Lymphoma 2001, 42:797-799.
63. Corazzelli G., Capobianco G., Russo F., et al. Pentostatin (2'-deoxycoformycin) for the treatment of hepatosplenic gammadelta T-cell lymphomas. Haematologica 2005, 90(March (3)):ECR14.
64. Humphreys M.R., Cino M., Quirt I., et al. Long-term survival in two patients with hepatosplenic T cell lymphoma treated with interferon-alpha. Leuk Lymphoma 2008, 49(July (7)):1420-1423.
65. Tey S.K., Marlton P.V., Hawley C.M., et al. Post-transplant hepatosplenic T-cell lymphoma successfully treated with HyperCVAD regimen. Am J Hematol 2008, 83(April (4)):330-333.
66. Rajakariar R., Bhattacharyya M., Norton A., et al. Post transplant T-cell lymphoma: a case series of four patients from a single unit and review of the literature. Am J Transplant 2004, 4(September (9)):1534-1538.
67. Jaeger G., Bauer F., Brezinschek R., et al. Hepatosplenic gammadelta T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine. Ann Oncol 2008, 19(May (5)):1025-1026.
68. Koenecke C., Czeloth N., Bubke A., et al. Alloantigen-specific de novo-induced Foxp3+ Treg revert in vivo and do not protect from experimental GVHD. Eur J Immunol 2009, 39(November (11)):3091-3096.
69. Bonder C.S., Clark S.R., Norman M.U., et al. Use of CD44 by CD4+ Th1 and Th2 lymphocytes to roll and adhere. Blood 2006, 107(June (12)):4798-4806.
70. Martinet L., Fleury-Cappellesso S., Gadelorge M., et al. A regulatory cross-talk between Vgamma9Vdelta2T lymphocytes and mesenchymal stem cells. Eur J Immunol 2009, 39(March (3)):752-762.